奥曲肽联合奥美拉唑治疗肝炎后肝硬化合并上消化道出血患者的疗效及对止血时间及不良反应的影响

摘要

Objective To investigate the efficacy of octreotide combined with omeprazole on treatment of patients with liveRcirrhosis and uppeRgastrointestinal bleeding and its influence on hemostasis time and adverse reactions.Methods A total of 80 patients with liveRcirrhosis and uppeRgastrointestinal bleeding were selected and divided into octreotide combined with omeprazole group (combined treatment group,n=40) and vasopressin group (monotherapy group,n=40).The clinical efficacy,hemostasis time,hospital stay,incidence of bleeding within 2 d and adverse events were analyzed between two groups.Results The total effective rate of the combined treatment group was 92.5%,which was significantly higheRthan 67.5% of the monotherapy group (P<0.05),the hemostasis time and hospital stay were significantly shorteRthan the monotherapy group (P<0.05).The 2 d re-bleeding rate of the combined treatment group was 7.5%,which was significantly loweRthan 27.5% of the monotherapy group (P<0.05),the incidence rate of adverse reactions was 2.5%,which was significantly loweRthan 22.5% of the monotherapy group (P<0.05).Conclusion Octreotide combined with omeprazole can effectively improve therapeutic effect,shorten hemostasis time and reduce adverse reactions in patients with liveRcirrhosis and uppeRgastrointestinal bleeding.%目的 探讨奥曲肽联合奥美拉唑对肝炎后肝硬化并上消化道出血患者治疗效果、止血时间及不良反应的影响.方法 选取肝炎后肝硬化并上消化道出血患者80例,依据随机数字表法分为奥曲肽联合奥美拉唑组(联合治疗组,n=40)和垂体后叶素组(单独治疗组,n=40).对2组患者的临床疗效、止血时间、住院时间、2 d内再出血发生情况及不良反应发生情况进行统计分析.结果 联合治疗组患者治疗的总有效率为92.5%,显著高于单独治疗组67.5%(P<0.05),止血时间、住院时间均显著短于单独治疗组(P<0.05),2 d内再出血率为7.5%,显著低于单独治疗组27.5%(P<0.05),不良反应发生率为2.5%,显著低于单独治疗组22.5%(P<0.05).结论 奥曲肽联合奥美拉唑能够有效改善肝炎后肝硬化并上消化道出血患者的治疗效果,缩短患者的止血时间,减少患者的不良反应.